Forum SIMSON JAWA ROMET (!!) Strona Główna
->
Romet Komar
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
NIE
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie EET (Europa)
Skocz do:
Wybierz forum
motorowery
----------------
Simson
Jawa
Romet Ogar
Romet Komar
problemy
----------------
problemy
sklepik
----------------
Kupię
sprzedam
zamienię
wasze
----------------
wasze motorowery
top lista
wasze motocykle
motocykle
----------------
motocykle
Przegląd tematu
<table border="0" cellpadding="3" cellspacing="1" width="100%" class="forumline"> <tr> <th class="thCornerL" width="22%" height="26">Autor</th> <th class="thCornerR">Wiadomość</th> </tr> <tr> <td width="22%" align="left" valign="top" class="row1"><span class="name"><a name=""></a><b>k19c8mj4xh</b></span></td> <td class="row1" height="28" valign="top"><table width="100%" border="0" cellspacing="0" cellpadding="0"> <tr> <td width="100%"><img src="http://picsrv.fora.pl/xeon/images/icon_minipost.gif" width="12" height="9" alt="Post" title="Post" border="0" /><span class="postdetails">Wysłany: Śro 6:49, 16 Lut 2011<span class="gen"> </span> Temat postu: WuXi PharmaTech Well Positioned to Continue Growin</span></td> </tr> <tr> <td colspan="2"><hr /></td> </tr> <tr> <td colspan="2"><span class="postbody">WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million. <br /> <br />"WuXi‘s strategy has not changed. Our goal is, and has long been, to build a broad, integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development,<a href="http://www.orbto.com/software-outsourcing/php-outsourcing/" target="_blank" class="postlink">PHP development outsourcing</a>," said Dr. Ge Li, Chairman and Chief Executive Officer. "While we are disappointed that this transaction could not be completed, WuXi remains well positioned to meet our customers‘ needs and to continue to grow and expand as a standalone company. <br /> <br />"All of our businesses are performing very well," Dr. Li continued. "Each business unit has met or exceeded its targets for the second quarter, and we recently increased our guidance for full-year 2010 financial performance. <br /> <br />"Virtually all of the large global pharmaceutical companies, as well as hundreds of smaller pharmaceutical and biotech companies and many leading medical device companies, are our customers,<a href="http://www.orbto.com/software-outsourcing/flash-web-development/" target="_blank" class="postlink">Flash development outsourcing</a>," Dr. Li concluded. "We believe that strong trends for greater outsourcing and offshoring of R&D services will continue, and that WuXi,<a href="http://www.orbto.com/software-outsourcing/quality-assurance-outsourcing/" target="_blank" class="postlink">Quality Assurance Outsourcing</a>, as the leading China-based contract research organization, is well positioned to benefit from this powerful outsourcing trend for many years to come." <br /> <br />Second Quarter Results <br /> <br />WuXi will report financial results for the second quarter ending June 30, 2010,<a href="http://www.orbto.com/business-process-outsourcing/data-entry-outsourcing/" target="_blank" class="postlink">Data processing outsourcing</a>, on Monday, August 2,<a href="http://www.orbto.com/company/why-orbto/" target="_blank" class="postlink">Outsourcing companies</a>, at 6:30 am EDT with a conference call at 8:30 am EDT to discuss the results and the outlook for WuXi‘s business. The conference call may be accessed by calling: <br /> <br /> United States: 1-866-519-4004 <br /> China (Landline): 800-819-0121 <br /> China (Mobile): 400-620-8038 <br /> Hong Kong: 800-930-346 <br /> United Kingdom: 0-808-234-6646 <br /> International: +65-6723-9381 <br /> Conference ID: 90840146 <br /> Web PIN: 8656 <br /> <br /> A replay will be available two hours after the call‘s completion at: <br /> <br /> United States: 1-866-214-5335 <br /> China North: 10-800-714-0386 <br /> China South: 10-800-140-0386 <br /> Hong Kong: 800-901-596 <br /> United Kingdom: 0-800-731-7846 <br /> International: +61-2-8235-5000 <br /> Passcode: 90840146 <br /> <br />A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech‘s website at .</span></td> </tr> </table></td> </tr> <tr> <td colspan="2" height="1" class="spaceRow"><img src="http://picsrv.fora.pl/xeon/images/spacer.gif" alt="" width="1" height="1" /></td> </tr> </table>
fora.pl
- załóż własne forum dyskusyjne za darmo
xeon Template ©
Digital-Delusion
Powered by
phpBB
© 2001, 2002 phpBB Group
Regulamin
